Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy

Ping Liang,Guihuai Wang,Xinyu Liu,Zhuoran Wang,Jing Wang,Weiping Gao
DOI: https://doi.org/10.1016/j.biomaterials.2020.120447
IF: 14
2021-01-01
Biomaterials
Abstract:<p>Cancer recurrence post surgical resection is of considerable challenge especially in glioblastoma (GBM) therapy. Herein, we demonstrate that interferon-alpha (IFN) fused to a body temperature-sensitive elastin-like polypeptide (IFN-ELP(V)) formed a depot in situ when injected into GBM resection cavity in a mouse brain orthotopic model of GBM. Notably, IFN-ELP(V) in the depot showed a zero-order release kinetics, resulting in dramatically improved pharmacokinetics and biodistribution, and thus inhibited GBM recurrence by stimulating antitumor immunoresponse as compared to IFN. More importantly, when combined with subsequent intraperitoneal injection of temozolomide (TMZ), IFN-ELP(V) could much more effectively suppress post-surgical GBM recurrence than IFN, leading to a remarkably enhanced GBM-free survival rate (60%) over IFN (12.5%). Our findings implicate that the spatiotemporally-programmed combination of IFN-ELP(V) and TMZ leads to the synergy of post-surgical GBM immunochemotherapy, thereby providing a new and effective strategy for cancer therapy.</p>
engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: **How to effectively inhibit the postoperative recurrence of glioblastoma (GBM)**. ### Specific problem background and challenges: 1. **Invasiveness and recurrence of GBM**: - Glioblastoma (GBM) is one of the most invasive brain tumors and is highly resistant to existing standard treatment methods (such as surgery, chemotherapy, and radiotherapy). - Although surgical techniques have made significant progress, it is almost impossible to completely remove all GBM cells without causing nerve damage, which leads to the inevitable recurrence of GBM. 2. **Problems with the treatment window period**: - There is a time window of about one month between the postoperative period and the start of chemotherapy or radiotherapy. During this period, chemotherapy or radiotherapy cannot be carried out immediately due to concerns about affecting wound healing, and this period is a critical period for GBM recurrence. 3. **Limitations of existing local drug delivery systems**: - The only local drug delivery system currently approved for clinical GBM treatment is the biodegradable Gliadel® patch containing carmustine, but its extension of survival time is limited (only two months), and side effects are frequent. 4. **Challenges of immunotherapy in GBM**: - Although immunotherapies such as anti - programmed death - 1 (PD - 1) antibodies have shown efficacy in many solid tumors, they have not shown positive results in human trials of GBM. This is because there are immunosuppressive characteristics in the GBM microenvironment, such as the lack of tumor - infiltrating lymphocytes and the large presence of immunosuppressive myeloid cells (such as M2 - like microglia and macrophages). ### Solutions proposed in the paper: To overcome the above challenges, the paper proposes a spatiotemporal - programmed combination therapy, that is, **using thermosensitive elastin - like polypeptide - fused interferon (IFN - ELP(V)) in combination with temozolomide (TMZ) for the immunochemotherapy of postoperative GBM**. Specifically: - **IFN - ELP(V)**: By fusing interferon (IFN) with a body - temperature - sensitive elastin - like polypeptide (ELP(V)), an in - situ drug reservoir can be formed after injection into the GBM resection cavity, and the drug can be slowly released with zero - order release kinetics, thereby improving pharmacokinetics and biodistribution, stimulating anti - tumor immune responses, and inhibiting GBM recurrence. - **TMZ**: As a first - line chemotherapy drug, TMZ is administered by intraperitoneal injection within two weeks after surgery to further enhance the anti - tumor effect and achieve a synergistic effect. ### Main research contents: - **Synthesis and characterization**: Synthesize and characterize IFN - ELP(V), and verify its temperature - responsive behavior and pharmacological properties. - **In vivo release and pharmacokinetics**: Study the sustained - release behavior and pharmacokinetic characteristics of IFN - ELP(V) in vivo, and find that it has a zero - order release characteristic for up to three weeks. - **Inhibition of GBM recurrence**: Through experiments on the mouse brain in - situ GBM model, verify the effect of IFN - ELP(V) used alone and in combination with TMZ on inhibiting GBM recurrence. - **Synergistic immunochemotherapy**: Prove that the combined use of IFN - ELP(V) and TMZ can significantly increase the GBM - free survival rate (60%), which is much higher than that of IFN used alone (12.5%) or other treatment groups. In conclusion, this study provides a new spatiotemporal - programmed combination therapy, aiming to effectively inhibit the postoperative recurrence of GBM and providing a new strategy for cancer treatment.